Home    Back

Tvp-1012    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
6Parkinson disease12

6. Parkinson disease    [ 2,123 clinical trials,   2,046 drugs,   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
12 / 2,123 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02337751
(ClinicalTrials.gov)		July 10, 20159/1/2015A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease ParticipantsA Multicenter, Open-label, Long-term, Extension, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With LevodopaParkinson's DiseaseDrug: TVP-1012 1mgTakedaNULLCompleted30 Years79 YearsAll198Phase 3Japan
2NCT02337725
(ClinicalTrials.gov)		February 7, 20159/1/2015A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease PatientsA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With LevodopaParkinson's DiseaseDrug: TVP-1012;Drug: PlaceboTakedaNULLCompleted30 Years80 YearsAll244Phase 3Japan
3NCT02337764
(ClinicalTrials.gov)		February 3, 20159/1/2015A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease ParticipantsA Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease PatientsParkinson's DiseaseDrug: TVP-1012 1mgTakedaNULLCompleted30 Years79 YearsAll222Phase 3Japan
4NCT02337738
(ClinicalTrials.gov)		January 27, 20159/1/2015A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease ParticipantsA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing OffParkinson's DiseaseDrug: TVP-1012 1mg;Drug: TVP-1012 0.5mg;Drug: PlaceboTakedaNULLCompleted30 Years79 YearsAll404Phase 2;Phase 3Japan
5JPRN-JapicCTI-152762
27/1/2015A long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease PatientsA Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease Patients Parkinson's diseaseIntervention name : TVP-1012 (1 mg/day) with levodopa
Dosage And administration of the intervention : TVP-1012 (1 mg/day) once daily, before or after breakfast. A levodopa combination drug will be concomitantly administered in principle without change in the dose regimen throughout the study period from the start of the screening period.
Control intervention name : null		TAKEDA PHARMACEUTICAL COMPANY LTD.NULL3079BOTH215Phase 3NULL
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6EUCTR2006-005140-89-NL
(EUCTR)		11/12/200601/12/2006A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS - Tyramine challenge studyA PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJECTS - Tyramine challenge study This postmarketing Phase I study is performed in healthy volunteers. The IMP rasagiline 1mg is indicated for the treatment of Parkinson's Disease (PD).
MedDRA version: 9.1;Level: PT;Classification code 10061536		Trade Name: Selegiline HCl 5 PCH
Trade Name: Nardil
Product Name: Rasagiline 1mg tablet
Product Code: TVP-1012
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesilate
Product Name: Rasagiline 2 mg tablet
Product Code: TVP-1012
INN or Proposed INN: Rasagiline
Other descriptive name: Rasagiline mesilate		TEVA Pharmaceuticals Industries LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		160Phase 1Netherlands
7EUCTR2005-001416-42-PT
(EUCTR)		07/11/200525/08/2005A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIOA Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO Parkinson's Disease
MedDRA version: 7.1;Level: PT;Classification code 10061536		Trade Name: AZILECT
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate		Teva Pharmaceuticals Industries LtDNULLNot RecruitingFemale: yes
Male: yes		1100Hungary;Portugal;Germany;United Kingdom;Spain;Italy
8EUCTR2005-001416-42-HU
(EUCTR)		27/09/200520/06/2005A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIOA Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO Parkinson's Disease
MedDRA version: 7.1;Level: PT;Classification code 10061536		Trade Name: AZILECT
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate		Teva Pharmaceuticals Industries LtDNULLNot RecruitingFemale: yes
Male: yes		1100Portugal;Hungary;Germany;United Kingdom;Spain;Italy
9EUCTR2005-001416-42-DE
(EUCTR)		01/09/200517/10/2005A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIOA Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO Parkinson's Disease
MedDRA version: 7.1;Level: PT;Classification code 10061536		Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate		Teva Pharmaceuticals Industries LtDNULLNot RecruitingFemale: yes
Male: yes		1100Portugal;Hungary;United Kingdom;Germany;Spain;Italy
10EUCTR2005-001416-42-AT
(EUCTR)		24/08/200520/07/2005A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIOA Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects - ADAGIO Parkinson's Disease
MedDRA version: 7.1;Level: PT;Classification code 10061536		Trade Name: AZILECT
Product Name: rasagiline tablets
Product Code: TVP-1012
INN or Proposed INN: rasagiline
Other descriptive name: rasagiline mesilate		Teva Pharmaceuticals Industries LtDNULLNot RecruitingFemale: yes
Male: yes		1100Portugal;Hungary;Spain;Austria;Germany;Italy;United Kingdom
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
11EUCTR2005-001416-42-IT
(EUCTR)		14/07/200521/06/2005A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease SubjectsA Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects Neuroprotective early treatment of Parkinson's disease subjects
MedDRA version: 6.1;Level: PT;Classification code 10061536		Product Name: NA
Product Code: NA
Other descriptive name: NA
Product Name: rasagiline
Product Code: TVP-1012		TEVANULLNot RecruitingFemale: yes
Male: yes		Portugal;Hungary;Germany;United Kingdom;Spain;Italy
12NCT00203125
(ClinicalTrials.gov)		October 200013/9/2005A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.Sub-study to Evaluate the Effect of An Oral Dose of Tyramine in Subjects Completing 26 Weeks of Participation in PRESTO (TVP-1012/133)Parkinson's DiseaseDrug: rasagiline mesylate;Other: tyramineTeva Pharmaceutical IndustriesNULLCompletedN/AN/ABoth55Phase 3United States

Back to top